The aim of this study was to evaluate the therapeutic efficacy of intravenous immunoglobulin (IVIG) in the prevention of recurrent spontaneous abortion (RSA). In a double-blind, randomized, placebo-controlled study, 41 women with a history of unexplained recurrent spontaneous abortion were treated with IVIG or saline infusions during pregnancy. The birth of a child was considered a successful outcome. The overall success rate was 77% in the IVIG group compared with 79% in the placebo group. For women with primary RSA the success rates were 82 (IVIG) and 89% (placebo), and for women with secondary RSA the rates were 73 (IVIG) and 70% (placebo). We found no statistically significant difference in treatment results between IVIG and placebo.
Introduction
Recurrent spontaneous abortion (RSA) is defined as three or more consecutive pregnancy losses and the condition affects 1% of all women (Clifford et al., 1994) . RSA is classified as either primary (never achieved a live birth) or secondary (normal pregnancy followed by recurrent abortion) (Heine and Mueller-Eckhardt, 1994) . It has been suggested that treatment with i.v. immunoglobulin could be an alternative to immunotherapy with allogenic leukocytes in patients with RSA (Carreras et al., 1988) .
The results of pilot studies were promising. The rate of successful pregnancies was 82% for women with RSA (Mueller-Eckhardt et al., 1989; Christiansen et al., 1992) . In a later study by Mueller-Eckhardt et al. (1991) , the success rate for IVIG treatment was 75% in primary and 60% secondary RSA patients.
We report here our results from a double-blind, randomized, placebo-controlled study on i.v. immunoglobulin in the treatment of unexplained RSA.
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Materials and methods
Study design
A double-blind, randomized, placebo-controlled study was done to evaluate the efficacy of i.v. immunoglobulin in the prevention of RSA. The study was approved by the Local Ethics Committee and the Medical Products Agency. The patients were classified as belonging to a primary or a secondary RSA group. Within each RSA group women were separately, centrally randomized by using sealed envelopes at the hospital pharmacy to IVIG or placebo treatment as soon as a transvaginal ultrasound scan had identified fetal heart activity. Based on the assumption that the absolute difference in success rate was 30%, and to obtain an increase from the stipulated 50-80%, we estimated that 80 women (40 in the IVIG and 40 in the placebo group), were needed to detect a statistically significant difference (P Ͻ 0.05) with reasonable power.
The study was run at the Departments of Obstetrics and Gynecology University Hospital, Linköping and Huddinge University Hospital.
Patients
Patients with primary RSA (without a live birth) or secondary (a live birth followed by consecutive spontaneous abortions) were included. RSA was defined as three or more consecutive fetal losses before the 20th gestational week. All previous pregnancy losses were confirmed by ultrasound or by histology. Data were taken from the hospital records. Inclusion criteria are presented in Table I . Women with enrollment in other clinical studies or previous inclusion in this study were excluded.
Treatment protocol
Women who fulfilled inclusion criteria were randomized to the IVIG or placebo group. Randomization was done separately for women with primary and secondary RSA.
IVIG and saline (placebo) could not be distinguished, and the codes were blind for both the patients and the hospital staff. IVIG and placebo were distributed 2 h after request and in identical, nontransparent plastic bags. Women received IVIG (20 g Gammonativ ® , 400 ml) or placebo (saline, 400 ml) every 3 weeks on five occasions if a viable pregnancy was confirmed by ultrasound before each treatment. By mistake, one patient with a successful outcome of her pregnancy in the IVIG group received only four infusions.
Study medication
Gammonativ ® (Pharmacia & Upjohn Plasma Products, Stockholm, Sweden) is a lyophilized powder of normal serum immunoglobulin of human origin aimed for i.v. use. The content of IgA in Gammonativ ® is very low (Ͻ0.02% of total protein content) and therefore IgA deficiency is not a contraindication for Gammonativ ® treatment. Gammonativ ® 20 g in 400 ml sterile water was prepared by the hospital pharmacy within 2 h before it was given to the patient as an i.v. infusion. 
Intravenous Ig for recurrent abortion
Measures of effect
The therapy was defined as successful if the pregnancy resulted in the delivery of a liveborn or stillborn child of either more than 28 weeks gestation or with a birthweight exceeding 999 g.
Statistics
The Mantel-Haenszel χ 2 test was used to compare treatment results between IVIG and placebo in the whole group as well as within subgroups. A P value Ͻ0.05 was considered as statistically significant. The Mann-Whitney U-test was used to compare the background data between the IVIG and placebo groups.
Results
From November 1993 to April 1997, 89 women with unexplained RSA were all investigated for possible inclusion in the study, and 44 of these became pregnant and a final 41 women were enrolled in the study. Two women had blighted ova and one woman had an ongoing miscarriage before the first IVIG treatment and they were therefore not enrolled in the study. No early pregnancy losses have been reported in the group of 45 women who did not achieve pregnancy during this study. Karyotyping of the products of conception was not performed. Treatment was started at gestational weeks 6-7 in all except four patients, who received the first infusion at 8 (n ϭ 3) or 9 (n ϭ 1) gestational weeks. The overall result was extremely good (80% pregnancies Ͼ28 weeks) in 39 patients. A half-time evaluation was therefore decided and we found that a result according to the primary hypothesis (a success rate increase from 50 to 80% with immunoglobulin treatment) could not be reached even with the originally proposed sample size. Consequently, the study was terminated for a final evaluation.
In the group of 41 patients that were finally evaluated (Table II) , 77% IVIG-treated and 79% placebo-treated women had live births (χ 2 ϭ 0.016, not significant). In the group of women with primary RSA, 82% of IVIG-treated and 89% of placebo-treated had live births (χ 2 ϭ 0.184, not significant). In the group with secondary RSA, 73% of IVIG-treated and 70% of placebo-treated women had live births (χ 2 ϭ 0.018, not significant). Thus, we found no statistically significant differences in treatment results between IVIG and placebo.
Background characteristics of the women in the IVIG and placebo groups are presented in Table III . The prevalence of recurrent spontaneous abortion in the IVIG and placebo groups is presented in Table IV .
The mean weight of the newborns was 3493 g (range 1090-5030) in the IVIG group and 3530 g (range 2780-4200) in the placebo group. The mean gestational ages were 38.9 weeks (range 27-42 weeks) in the IVIG group and 39.6 weeks (range 38-41 weeks) in the placebo group. There was only one preterm delivery, in the IVIG group. No congenital malformations were observed in the newborns.
Six women belonging to the IVIG group reported mild skin rashes and itching (n ϭ 1), moderate skin rashes and itching (n ϭ 1), elevated body temperature (n ϭ 2), flush (n ϭ 1) and severe vaginal bleeding (n ϭ 1). Two women in the placebo group reported severe itching (n ϭ 1) and mild vaginal bleeding (n ϭ 1).
Discussion
We examined the efficacy of IVIG to prevent recurrent spontaneous abortion and found that there was no significant difference in rates of successful pregnancies between IVIG and placebo treatment. The criteria for eligibility to our study prevented inclusion of women with anticardiolipin antibodies, elevated APTT and presence of antinuclear antibodies. The study group was selected to investigate RSA of unknown cause. In a retrospective, recently published overview, data available on the possible causes of failure due to spontaneous abortion, recurrent miscarriage and treatment have been reported (Bulletti et al., 1996) . It has been suggested that some of the idiopathic recurrent miscarriages might be due to immunological factors (Lim et al., 1996) and the derangement in cytokine profiles during pregnancy would be influential in determining a T helper cells type 1 or T helper cells type 2 immune response (Mosmann et al., 1986) . In our study 37 women were included in gestational weeks 6-7 after transvaginal ultrasound scanning had identified fetal heart activity. Three women were included in gestational week 8 and one in gestational week 9. In the Danish study, all patients were enrolled and infusions were started in the fifth gestational week (Christiansen et al., 1995) . In the German study, patients were enrolled between 5 and 8 weeks of pregnancy (The German RSA/IVIG group, 1994). Treatment was initiated before conception in the American trial (Coulam et al., 1995) and in the Canadian trial (Stephenson et al., 1998) . In this way, women who would succumb to very early spontaneous abortion were included. The selection criteria and the time of the first infusion of IVIG or placebo might account for the higher pregnancy rate in this study. However, we have observed few abortions at gestational ages Ͻ6 weeks in the group of women enrolled to participate in the study. Thus, using the patient selection criteria and treatment protocol reported in the present trial, IVIG seems to lack significant therapeutic effectiveness. We also found that 79% of women in the placebo group had babies, which was far better than the presumed 50% that we derived from historical data and used in our calculations. A recent study (Clifford et al., 1997) showed that nearly 70% of women with first trimester unexplained recurrent spontaneous abortion could achieve a livebirth in the next pregnancy with supportive care alone. The success rate was nearly 80% if women were aged Ͻ40 years and number of previous miscarriages was less than six. Due to the result of the half time evaluation, the study was terminated and only half of the planned number of patients was included. This makes the estimate of the true treatment results for IVIG and placebo more uncertain, i.e. the 95% confidence intervals were wide for all groups. Hence, our data are insufficient to test the original hypothesis.
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The results of studies published before this study was started were promising (Mueller-Eckhardt et al., 1989 , 1991 Christiansen et al., 1992) . Before this study was completed, three placebo-controlled studies were published. One study showed that IVIG treatment was beneficial (Coulam et al., 1995) whereas two other studies could not demonstrate that IVIG treatment was efficient (The German RSA/IVIG Group, 1994; Christiansen et al., 1995) . However, when the results of these placebo-controlled trials were summarized, a significant result was achieved (Christiansen, 1996) . The success rate was 840 64% in the IVIG group and 47% in the placebo group (P Ͻ 0.05). Recently two placebo-controlled studies (Perino et al., 1997; Stephenson et al., 1998) have shown no effect of IVIG in RSA patients.
We observed, like other authors (Clifford et al., 1994) , that some of the couples had difficulties in becoming pregnant and it is also known that patients who achieve pregnancy more quickly might also have a better prognosis (Clark and Coulam, 1996) . It is therefore not certain that the observed 'baby rate' after three consecutive spontaneous abortions is close to 80%.
We used saline as placebo in this study in contrast to most previously published placebo-controlled studies where albumin was used in different concentrations: 5% albumin (The German RSA/IVIG Group, 1994), 1.5% albumin (Christiansen et al., 1995) and 0.5% (Coulam et al., 1995) . The role of albumin as placebo has been questioned (Rewald et al., 1995) . An immunomodulating effect of albumin in concentrations Ͼ0.5% could not be excluded (Coulam et al., 1995) . In a recently published study, saline was used as placebo (Stephenson et al., 1998) .
A pregnancy loss is an emotional event for the couple. The positive role of psychological influence ('tender loving care') has been demonstrated for pregnancy success in women with RSA (Stray-Pedersen and Stray-Pedersen, 1984) . The excellent outcome of pregnancy after unexplained recurrent first trimester miscarriage with supportive care alone has been documented recently (Clifford et al., 1997) . We can neither deny nor verify that we have had such an effect in both IVIG and placebo groups in our study.
To conclude, we found that women with RSA have a better prognosis than presumed and that IVIG does not improve the prognosis compared to placebo in a setting where the couples are given extra care.
